{"id":"ganirelix-acetate-cetrolix-acetate","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Ovarian hyperstimulation syndrome (OHSS)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Abdominal pain/discomfort"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These peptide antagonists competitively bind to GnRH receptors on pituitary gonadotroph cells, rapidly suppressing gonadotropin release without an initial flare effect. This prevents premature LH surge during controlled ovarian hyperstimulation, allowing precise timing of oocyte retrieval in assisted reproductive technology cycles.","oneSentence":"Ganirelix and Cetrolix are gonadotropin-releasing hormone (GnRH) antagonists that block GnRH receptors to suppress luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:12.028Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Controlled ovarian hyperstimulation in women undergoing assisted reproductive technology (ART) / in vitro fertilization (IVF)"}]},"trialDetails":[{"nctId":"NCT04993924","phase":"PHASE4","title":"GnRH Antagonist Pre-treatment in the Early Follicular Phase for Resolution of a Baseline Functional Ovarian Cyst","status":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"2021-05-01","conditions":"IVF, Ovarian Cysts","enrollment":15},{"nctId":"NCT05071339","phase":"PHASE4","title":"GnRH Antagonist Pre-treatment for the Prevention of Asynchronous Follicular Growth","status":"UNKNOWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"2021-04-01","conditions":"IVF","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ganirelix Acetate, Cetrolix Acetate","genericName":"Ganirelix Acetate, Cetrolix Acetate","companyName":"Assaf-Harofeh Medical Center","companyId":"assaf-harofeh-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ganirelix and Cetrolix are gonadotropin-releasing hormone (GnRH) antagonists that block GnRH receptors to suppress luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. Used for Controlled ovarian hyperstimulation in women undergoing assisted reproductive technology (ART) / in vitro fertilization (IVF).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}